<DOC>
	<DOC>NCT01938417</DOC>
	<brief_summary>This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset® T).</brief_summary>
	<brief_title>Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute</brief_title>
	<detailed_description />
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Adult (&gt; or =18 years old) patients Treatment with Osteoset® T Intravenous tobramycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>tobramycin</keyword>
	<keyword>bone graft substitute</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>renal failure</keyword>
</DOC>